<p>根據 XTX Topco Ltd 最近向證券交易委員會提交的 13F 文件，該公司在第四季度減少了對諾華製藥 (NYSE:NVS - 免費報告) 的持股 66.0%。在該季度出售了 20,140 股後，該公司持有 10,379 股諾華的股票。根據其最近向證券交易委員會的文件，XTX Topco Ltd 在諾華的持股價值為 1,010,000 美元。</p>
<ul>
<li>製藥巨頭盈利超預期，但股價下跌</li>
</ul>
<p>其他幾家對沖基金也增加或減少了對該公司的投資。Raymond James Financial Inc.在第四季度購買了諾華的股份，投資額約為 88,339,000 美元。Renaissance Technologies LLC 在第四季度將其在諾華的持股增加了 16.0%。Renaissance Technologies LLC 目前持有 2,668,849 股諾華的股票，價值 259,706,000 美元，此前在該期間又購買了 368,171 股。Fisher Asset Management LLC 在第四季度將其在諾華的持股增加了 17.4%。Fisher Asset Management LLC 目前持有 2,002,959 股諾華的股票，價值 194,908,000 美元，此前在該期間又購買了 296,950 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在諾華的持股增加了 128.1%。Mirae Asset Global Investments Co. Ltd.目前持有 528,682 股諾華的股票，價值 51,554,000 美元，此前在上個季度又購買了 296,890 股。最後，Proficio Capital Partners LLC 在第四季度購買了諾華的新股份，投資額為 225,000 美元。13.12% 的股票由機構投資者持有。</p>
<h2>諾華股票上漲 0.3%</h2>
<p>週三，NYSE:NVS 的開盤價為 109.84 美元。該公司的債務與股本比率為 0.48，流動比率為 1.04，速動比率為 0.84。該公司的 50 日移動平均價格為 109.01 美元，200 日移動平均價格為 106.36 美元。該公司的市值為 2245.2 億美元，市盈率為 18.68，市盈增長比率為 1.70，貝塔值為 0.56。諾華製藥的 1 年最低價為 92.35 美元，1 年最高價為 120.92 美元。</p>
<ul>
<li>20 只最佳醫療保健分紅股票投資指南</li>
</ul>
<p>諾華 (NYSE:NVS - 獲取免費報告) 最近一次公佈財報是在 1 月 31 日，報告每股收益為 1.98 美元，超出分析師一致預期的 1.80 美元，超出幅度為 0.18 美元。諾華的淨利潤率為 23.56%，股本回報率為 37.24%。分析師平均預測諾華製藥在當前財年的每股收益為 8.45 美元。</p>
<h2>諾華分紅公告</h2>
<p>該公司最近宣佈了一項分紅，已於 3 月 12 日支付。3 月 12 日的股東獲得了 3.8695 美元的分紅。除息日為 3 月 12 日。諾華的分紅支付比率 (DPR) 為 42.69%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>Voyager Therapeutics 股票因與諾華達成交易而上漲 30%</li>
</ul>
<p>NVS 最近受到幾份分析師報告的關注。摩根士丹利在 2 月 12 日的研究報告中對諾華的股票進行了覆蓋，給予了 “減持” 評級。瑞銀集團在 2 月 13 日的研究報告中重申了對諾華的 “中性” 評級。StockNews.com 在 2 月 8 日的研究報告中將諾華的評級從 “買入” 上調至 “強力買入”。巴克萊在 2 月 3 日的報告中重申了對諾華的 “減持” 評級。最後，德意志銀行在 2 月 4 日的報告中將諾華的評級從 “持有” 上調至 “買入”。三位投資分析師對該股票給予了賣出評級，六位給予了持有評級，一位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 123.38 美元。</p>
<p><strong>閲讀我們關於 NVS 的最新研究報告</strong></p>
<h2>關於諾華</h2>
<p>(免費報告)</p>
<p>諾華製藥公司在瑞士及國際上從事醫療產品的研究、開發、生產和營銷。該公司為患者和醫生提供處方藥。其重點領域包括心血管、腎臟和代謝、免疫學、神經科學和腫瘤學，以及眼科和血液學。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過諾華</li>
<li>什麼是分紅成就者？簡介</li>
<li>小心 BigBear.ai：內部人士正在出售——你應該注意嗎？</li>
<li>什麼是便士股票？全面指南</li>
<li>CrowdStrike 股票在網絡威脅環境擴大的情況下值得購買</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在諾華嗎？</h2>
<p>在考慮諾華之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而諾華並不在名單上。</p>
<p>雖然諾華目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

諾華制藥

<p>根據最近的 SEC 文件，XTX Topco Ltd 在第四季度將其在諾華製藥（NYSE:NVS）的持股比例減少了 66%。在出售了 20,140 股後，現持有 10,379 股，價值約為 1,010,000 美元。其他對沖基金也調整了在諾華的持倉。該股票開盤價為 109.84 美元，市值為 2245.2 億美元，市盈率為 18.68。諾華最近報告每股收益為 1.98 美元，超出預期，並宣佈每股派息 3.8695 美元</p>

<p>XTX Topco Ltd lessened its holdings in Novartis AG (NYSE:NVS - Free Report) by 66.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 10,379 shares of the company's stock after selling 20,140 shares during the quarter. XTX Topco Ltd's holdings in Novartis were worth $1,010,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根據 XTX Topco Ltd 最近向證券交易委員會提交的 13F 文件，該公司在第四季度減少了對諾華製藥 (NYSE:NVS - 免費報告) 的持股 66.0%。在該季度出售了 20,140 股後，該公司持有 10,379 股諾華的股票。根據其最近向證券交易委員會的文件，XTX Topco Ltd 在諾華的持股價值為 1,010,000 美元。</p>
</div><ul>
<li>Pharma Leader Beats on Earnings, But Shares Fall</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥巨頭盈利超預期，但股價下跌</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of Novartis in the fourth quarter worth about $88,339,000. Renaissance Technologies LLC increased its stake in Novartis by 16.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,668,849 shares of the company's stock worth $259,706,000 after purchasing an additional 368,171 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Novartis by 17.4% during the fourth quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company's stock valued at $194,908,000 after purchasing an additional 296,950 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novartis by 128.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company's stock worth $51,554,000 after purchasing an additional 296,890 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in Novartis during the 4th quarter valued at $225,000. 13.12% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金也增加或減少了對該公司的投資。Raymond James Financial Inc.在第四季度購買了諾華的股份，投資額約為 88,339,000 美元。Renaissance Technologies LLC 在第四季度將其在諾華的持股增加了 16.0%。Renaissance Technologies LLC 目前持有 2,668,849 股諾華的股票，價值 259,706,000 美元，此前在該期間又購買了 368,171 股。Fisher Asset Management LLC 在第四季度將其在諾華的持股增加了 17.4%。Fisher Asset Management LLC 目前持有 2,002,959 股諾華的股票，價值 194,908,000 美元，此前在該期間又購買了 296,950 股。Mirae Asset Global Investments Co. Ltd.在第四季度將其在諾華的持股增加了 128.1%。Mirae Asset Global Investments Co. Ltd.目前持有 528,682 股諾華的股票，價值 51,554,000 美元，此前在上個季度又購買了 296,890 股。最後，Proficio Capital Partners LLC 在第四季度購買了諾華的新股份，投資額為 225,000 美元。13.12% 的股票由機構投資者持有。</p>
</div><h2>Novartis Stock Up 0.3 %</h2>
<div class="lb-trans"><h2>諾華股票上漲 0.3%</h2>
</div><p>NYSE:NVS opened at $109.84 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The firm's 50-day moving average price is $109.01 and its 200-day moving average price is $106.36. The company has a market capitalization of $224.52 billion, a PE ratio of 18.68, a P/E/G ratio of 1.70 and a beta of 0.56. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.</p>
<div class="lb-trans"><p>週三，NYSE:NVS 的開盤價為 109.84 美元。該公司的債務與股本比率為 0.48，流動比率為 1.04，速動比率為 0.84。該公司的 50 日移動平均價格為 109.01 美元，200 日移動平均價格為 106.36 美元。該公司的市值為 2245.2 億美元，市盈率為 18.68，市盈增長比率為 1.70，貝塔值為 0.56。諾華製藥的 1 年最低價為 92.35 美元，1 年最高價為 120.92 美元。</p>
</div><ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><ul>
<li>20 只最佳醫療保健分紅股票投資指南</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, equities analysts predict that Novartis AG will post 8.45 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>諾華 (NYSE:NVS - 獲取免費報告) 最近一次公佈財報是在 1 月 31 日，報告每股收益為 1.98 美元，超出分析師一致預期的 1.80 美元，超出幅度為 0.18 美元。諾華的淨利潤率為 23.56%，股本回報率為 37.24%。分析師平均預測諾華製藥在當前財年的每股收益為 8.45 美元。</p>
</div><h2>Novartis Dividend Announcement</h2>
<div class="lb-trans"><h2>諾華分紅公告</h2>
</div><p>The business also recently announced a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 42.69%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項分紅，已於 3 月 12 日支付。3 月 12 日的股東獲得了 3.8695 美元的分紅。除息日為 3 月 12 日。諾華的分紅支付比率 (DPR) 為 42.69%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Voyager Therapeutics stock pops 30% on deal with Novartis</li>
</ul>
<div class="lb-trans"><ul>
<li>Voyager Therapeutics 股票因與諾華達成交易而上漲 30%</li>
</ul>
</div><p>NVS has been the subject of several recent analyst reports. Morgan Stanley assumed coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an &#34;underweight&#34; rating for the company. UBS Group reiterated a &#34;neutral&#34; rating on shares of Novartis in a research report on Thursday, February 13th. StockNews.com raised Novartis from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, February 8th. Barclays reiterated an &#34;underweight&#34; rating on shares of Novartis in a report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, February 4th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of &#34;Hold&#34; and an average target price of $123.38.</p>
<div class="lb-trans"><p>NVS 最近受到幾份分析師報告的關注。摩根士丹利在 2 月 12 日的研究報告中對諾華的股票進行了覆蓋，給予了 “減持” 評級。瑞銀集團在 2 月 13 日的研究報告中重申了對諾華的 “中性” 評級。StockNews.com 在 2 月 8 日的研究報告中將諾華的評級從 “買入” 上調至 “強力買入”。巴克萊在 2 月 3 日的報告中重申了對諾華的 “減持” 評級。最後，德意志銀行在 2 月 4 日的報告中將諾華的評級從 “持有” 上調至 “買入”。三位投資分析師對該股票給予了賣出評級，六位給予了持有評級，一位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 123.38 美元。</p>
</div><p><strong>Read Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 NVS 的最新研究報告</strong></p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>關於諾華</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>諾華製藥公司在瑞士及國際上從事醫療產品的研究、開發、生產和營銷。該公司為患者和醫生提供處方藥。其重點領域包括心血管、腎臟和代謝、免疫學、神經科學和腫瘤學，以及眼科和血液學。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>What is Short Interest? How to Use It</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過諾華</li>
<li>什麼是分紅成就者？簡介</li>
<li>小心 BigBear.ai：內部人士正在出售——你應該注意嗎？</li>
<li>什麼是便士股票？全面指南</li>
<li>CrowdStrike 股票在網絡威脅環境擴大的情況下值得購買</li>
<li>什麼是空頭頭寸？如何使用它</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在諾華嗎？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮諾華之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而諾華並不在名單上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然諾華目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

XTX Topco Ltd 減少了其在諾華製藥（NYSE:NVS）的持股